Novocure Ltd
NASDAQ:NVCR

Watchlist Manager
Novocure Ltd Logo
Novocure Ltd
NASDAQ:NVCR
Watchlist
Price: 17.73 USD 3.74% Market Closed
Market Cap: 1.9B USD
Have any thoughts about
Novocure Ltd?
Write Note

Novocure Ltd
Other Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Novocure Ltd
Other Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Items CAGR 3Y CAGR 5Y CAGR 10Y
Novocure Ltd
NASDAQ:NVCR
Other Items
$21.2m
CAGR 3-Years
N/A
CAGR 5-Years
53%
CAGR 10-Years
N/A
No Stocks Found

Novocure Ltd
Glance View

Market Cap
1.9B USD
Industry
Health Care

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The firm is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline. In addition to its clinical and commercial progress in GBM, it is planning or conducting clinical trials evaluating the use of TTFields in brain metastases, non-small-cell lung cancer (NSCLC), pancreatic cancer, ovarian cancer and mesothelioma. TTFields are delivered through a portable, medical device. The complete delivery system, which is designed to allow patients to go about their daily activities while receiving continuous cancer treatment, includes a portable electric field generator, transducer arrays, rechargeable batteries and accessories.

NVCR Intrinsic Value
24.31 USD
Undervaluation 27%
Intrinsic Value
Price

See Also

What is Novocure Ltd's Other Items?
Other Items
21.2m USD

Based on the financial report for Sep 30, 2024, Novocure Ltd's Other Items amounts to 21.2m USD.

What is Novocure Ltd's Other Items growth rate?
Other Items CAGR 5Y
53%

Back to Top